<.p>Recent clinical findings published in JAMA Oncology reveal that tracking patient-reported outcomes via a digital application significantly reduces fatigue and improves physical functioning in women with metastatic breast cancer. According to data from 52 German breast cancer centers, structured weekly symptom monitoring via the PRO-B app allows care teams to intervene rapidly when health changes occur.
Digital Symptom Tracking and Fatigue Reduction in Metastatic Breast Cancer
The multi-center, randomized clinical trial followed more than 900 women between May 2021 and February 2024 over a 12-month period, according to the published study. Half of the participants received standard medical tumor therapy alongside the PRO-B app monitoring concept, while control group participants were only surveyed every three months without direct clinical follow-up based on those responses. Through the app, patients answered up to 52 structured questions weekly regarding pain, fatigue, and emotional well-being. An automated algorithm flagged relevant changes, prompting medical staff to contact patients by telephone within 48 hours to determine necessary interventions.
At the six-month mark, the adjusted mean fatigue score in the intervention group dropped to 54.5 compared to 59.9 in the control group, marking a statistically significant mean difference of -5.4 points according to trial data. Physical functioning also scored higher in the intervention cohort, with a mean difference of 4.0 points. Following these positive outcomes, the Gemeinsame Bundesausschuss (G-BA) recommended integrating the treatment concept into standard medical care, backed by German health insurers BARMER, DAK-Gesundheit, and mkk – meine krankenkasse.
Circulating Tumor DNA Monitoring in Non-Small Cell Lung Cancer
In advanced non-small cell lung cancer (NSCLC), analyzing circulating tumor DNA (ctDNA) within weeks of starting immune checkpoint inhibitor therapy helps predict patient response, according to researchers in Boston publishing in Clinical Cancer Research. The study analyzed 328 plasma samples from 109 patients to observe ctDNA dynamics during the initial weeks of treatment.
Patients whose ctDNA became undetectable three to nine weeks after starting therapy experienced a median progression-free survival of 26.6 months, compared to just 3.4 months for patients with persistently detectable ctDNA, according to the study. Median overall survival reached 46.9 months in the undetectable ctDNA group versus 11.4 months for those with detectable levels. This blood-based biomarker analysis offers clinicians a way to identify treatment responders much earlier than conventional imaging and evaluation methods allow.
Opportunistic Salpingectomy for Ovarian Cancer Prevention
Removing the fallopian tubes during unrelated pelvic or abdominal surgeries significantly lowers the risk of tubo-ovarian carcinoma without harming short-term ovarian reserve, according to a consensus statement published in JAMA by an international working group of the European Society of Gynaecological Oncology. Based on a comprehensive review of 129 studies, the organization recommends that physicians include opportunistic salpingectomy in preoperative discussions for average-risk women who have completed their families.
The procedure extends operating times only slightly and does not increase perioperative risks, matching similar preventive guidance issued by the American College of Surgeons and the American Cancer Society. Experts advise considering the technique during elective non-gynecological pelvic procedures and select abdominal surgeries, alongside routine gynecological interventions.
Pediatric AML Trial Evaluating Liposomal Daunorubicin and Cytarabin
A phase 3 clinical trial conducted by the Children’s Oncology Group demonstrates that the combination of liposomal daunorubicin and cytarabin (CPX-351) falls short of standard induction therapy in children and young adults with newly diagnosed acute myeloid leukemia (AML). Published in the Journal of Clinical Oncology, the AAML1831 trial randomized 721 FLT3 wild-type AML patients to receive either standard daunorubicin and cytarabin (DA) or the liposomal formulation.
An interim analysis revealed lower efficacy for CPX-351, leading to the early cessation of randomization. Two-year event-free survival reached a certain percentage under standard DA treatment compared to a lower percentage under the CPX-351 regimen, according to trial findings. Furthermore, the liposomal treatment arm exhibited stronger myelosuppression, resulting in higher rates of bacterial infections and sepsis.
Population-Based Screening for Monoclonal Gammopathies in Iceland
The population-based iStopMM study in Iceland shows that screening for monoclonal gammopathies of undetermined significance (MGUS) identifies multiple myeloma earlier, according to results published in the Journal of Clinical Oncology. Out of participants tested between 2016 and 2020—representing 53% of invited residents born in 1975 or earlier—researchers detected MGUS in a subset of individuals.
Participants diagnosed with MGUS were randomized into control and intervention groups. While screening led to a 27-fold increase in the detection of smoldering multiple myeloma and diagnosed active multiple myeloma roughly one year earlier, researchers found no evidence that knowing an MGUS status caused psychological distress. However, study authors noted that the high volume of detected MGUS cases relative to early-detection benefits makes a broad, universal screening program economically challenging.
Management Strategies for Smoldering Multiple Myeloma
The clinical management of asymptomatic smoldering multiple myeloma (SMM) involves balancing early intervention against watchful waiting, according to an overview by Prof. Dr. Maria-Victoria Mateos published in the Journal of Clinical Oncology. While risk models like the 20/20/20 standard help identify high-risk patients—incorporating free light chain ratios, M-protein levels, and bone marrow plasma cell percentages—uncertainty remains regarding whether early treatment alters overall survival.
Mateos advocates for a risk-adapted approach, reserving early therapeutic intervention with agents such as daratumumab for carefully selected high-risk or ultra-high-risk patients. For low- and intermediate-risk SMM patients, active surveillance remains standard practice, minimizing unnecessary drug toxicity and healthcare costs while leveraging improved monitoring tools to catch disease progression promptly.
Related reading